We have assembled a group of world-class professionals, committed to changing the world one injection at a time.
Executive Chairman & Chief Executive Officer
Jay Walker leads ApiJect’s board of directors and leads the company’s operations as its Chief Executive Officer.
A serial entrepreneur, Mr. Walker has founded three companies that have gone from launch to 50 million customers each. He is the world’s 10th most patented inventor, named on more than 950 issued U.S. and international patents in technology-related fields.
Active in the field of medicine since 2012, Mr. Walker serves as Director and Curator of TEDMED, the health and medicine edition of the world-famous TED Conference. He is also Chairman of Upside, a travel and technology company that serves the unmanaged business traveler. A passionate student and practitioner of imagination, Mr. Walker founded and curated the Library of the History of Human Imagination, which Wired Magazine called, “the most amazing private library in the world.”Learn More
Founder & Head of Product Design
The inventor of ApiJect’s breakthrough BFS injection device is Marc Koska, one of the world’s most respected and successful social entrepreneurs.
In the mid-1980s, Mr. Koska invented the K-1 Auto-Disable Syringe, a device that stops the spread of blood-borne diseases and infection by making it impossible to reuse medical needles and syringes. In 2005, he founded the nonprofit SafePoint Trust to educate children about the dangers of employing used needles.
To date, Marc’s invention and leadership are estimated to have saved 12 million lives. In 2015, WHO director, Dr. Margaret Chan announced a new global policy on injection safety, promoting Auto-Disable syringes. The K-1 is now licensed and manufactured by 14 global manufacturers. Among many other honors bestowed upon Mr. Koska, he was made an Officer of the Order of the British Empire for his “contribution to global healthcare.”Learn More
Franco Negron Segarra is Vice-Chairman of ApiJect, where he advises and helps guide the company’s partnerships with leading pharmaceutical, biotech, and manufacturing service companies.
Mr. Negron’s experience in the pharmaceutical industry spans nearly 25 years. Previously, he served most recently as President of Commercial Operations of Thermo Fisher Scientific. Earlier posts with Themo Fisher included serving as President, TFS Drug Product Services and Product Development Services North America, following TFS’s acquisition of Patheon Pharmaceuticals.
He joined Thermo-Fisher in 2017 when it acquired his previous employer, Patheon Pharmaceuticals, where he served as President of Development & Commercial, North America. Shortly after the acquisition he was named President of Commercial Operations for the newly formed Pharma Services Group.
Prior to his post at Patheon, Mr. Negron was Vice President of Manufacturing and Supply at Valeant Pharmaceuticals, Global Vice President in Novartis’ Consumer Health Over-the-Counter and Pharmaceutical Products Division, and Site General Manager at McNeil Consumer Healthcare.
Hanjin In is Chairman and CEO of Tae-Chang Industrial Co., Ltd. of South Korea (T-C), an ApiJect partner as well as a leading global manufacturer of needle products and blood bags. Since 2006 he has served as CEO and Chairman for both TCI and its Kovac-Med company, which manufactures specialty precision injection products. Over the past decade, as a Director of a growing number of TCI affiliates from Indonesia to France and Florida, he has also overseen all company operations worldwide.
Established more than 25 years ago as an OEM, T-C today exports to more than 50 nations, including the U.S. and Japan, and serves as an OEM supplier to all major medical suppliers in the region. All of T-C’s products are GMP, ISO and CE certified. In addition to being a manufacturing partner, T-C is a key R&D contributor on the ApiJect Needle Hub component.Learn More
Chief Operations Officer
Mr. Guidotti comes to ApiJect with more than 30 years of pharma experience in global business, operational strategy and execution, supply chain management, manufacturing network design, and capital project planning and execution. From 2009 to 2020, he served in a variety of executive leadership roles with Patheon Pharmaceuticals and Thermo Fisher Scientific (which acquired Patheon in August 2017).
Most recently he was Group Vice President of Global Engineering, Capacity Planning, and Technical/Operations Services for Pharma Services Group within Thermo Fisher. His previous experience includes posts with Myers Squibb and Johnson Controls. As an industry consultant, he also supported a number of multinational pharma companies in improving operational and financial performance.
As ApiJect COO, Mr. Guidotti works closely with CEO Franco Negron on realizing the company’s growth strategy and continuing to build a world-class team in support of the delivery of the ApiJect platform.
Chief People Officer
Ms. Stewart is a Human Resources executive with 25 years of experience maximizing investment in human capital for organizations, including the past 15 years in the pharmaceutical industry.
From 2018 to 2020 she was the Executive Director Human Resources, Workforce Development and Talent Management at Eurofins Scientific, where she worked with the leadership team to lead and develop the workforce and talent management strategy to include recruiting and talent acquisition and managerial and talent development programs.
She previously served as Chief Human Resource Officer for Biomedical Systems Corp. from 2014 to 2018, following earlier stints there as Human Resources Manager and then as Director of Human Resources from 2010 to 2014. She was Recruiting Manager at Convergys Corp. from 2006 to 2008.
As a solutions-oriented change leader, Ms. Stewart seeks to balance people strategy with business strategy while demonstrating agility and collaboration throughout organizations.
EVP & Global Head of M&A
Peter Stone has over 25 years’ experience in private equity, mergers & acquisitions and corporate finance, and as CFO of both private and publicly traded companies both domestically and internationally. He has completed over 30 acquisitions and 20 equity/debt financings, corporate turnarounds and restructurings. His international operations and management experience includes Canada, Mexico, Latin and South America and ANZAC.
Mr. Stone began his private equity and M&A career at Deutsche Bank, followed by Mercury Capital and The Seabury Group. He gained his CFO and operations experience in a wide range of industries, including technology, manufacturing, travel, professional services and now healthcare. Prior to joining ApiJect he was Chief Financial Officer of the Americas for
Flight Centre Travel Group, a division of Flight Centre Travel Group Ltd, a $4 billion market cap publicly-traded Australian global travel services leader headquartered in Brisbane, Australia with leading operations in 97 countries around the world.
Acting Chief Financial Officer
Ms. Markovich, who also serves as the company’s VP and Corporate Controller, is a strategic finance executive with more than 25 years’ accounting and finance experience in a big four public accounting firm, as well as public corporations and private equity-backed companies.
From 2019 to 2021 she was VP, Global Controller for Vyaire Medical, a private equity-backed global respiratory company that spun off from Becton Dickinson in 2016. She led global accounting, financial reporting, accounts receivable, accounts payable and tax organizations consisting of over 100 professionals in seven locations worldwide.
Earlier, Ms. Markovich was VP, Chief Accounting Officer and Controller at Cars.com from 2017 to 2019 in its spinoff as a public company. Her prior career included increasingly responsible accounting and financial management posts from 1996 onward with companies such as PricewaterhouseCoopers, Qwest Communications International, Siemens Healthcare Diagnostics, Midway Games, Dover Corp. and CDW Corp.
Senior Adviser to the Chairman
Jon Ellenthal has devoted 30 years to starting, building, and leading early-stage companies that seek to change how an established industry does business. Prior to ApiJect, he was a Co-Founder and Board Member of The Upside Travel Company, a corporate travel tech company. Mr. Ellenthal has served as the Chief Executive Officer of Walker Digital, a private R&D lab for business innovation. He is a Founding Patron and former President of TEDMED, the independently owned and operated health and medical edition of the world-famous TED organization.
Earlier, Mr. Ellenthal was the CEO of Synapse Group, Inc. In 10 years, Synapse grew from an idea with seed capital to a company with an exit valuation approaching $1B. Prior to becoming CEO, Mr. Ellenthal served in a variety of senior leadership roles at Synapse.Learn More
Sr. Director, Supply Chain
Josh Myers is Senior Director, Supply Chain at ApiJect. Before joining the company, he helped run the commercial operations group in North America for Unither Pharmaceuticals, a leading BFS contract manufacturer. He spent two years at Unither helping transform the North American business unit from a traditional oral dose manufacturing site to a leading sterile BFS producer within Unither. His experience there includes serving as Interim Commercial Director – North America from 2019 to 2020.
As Sr. Director of Supply Chain at ApiJect, he helps bridge the commercial operations with the technical group while interfacing with key stakeholders both internally and externally. Mr. Myers also brings to his post a diverse background with experience in contract manufacturing and food and beverage manufacturing. Prior to Unither, Mr. Myers spent seven years at North American Breweries in a number of different functional areas including operations, quality, product development, project management, and contract manufacturing.
Chief Compliance Officer & General Counsel
James (Jim) Garrett’s role at ApiJect includes expanding the company’s legal and governance infrastructure, and, as a member of the ApiJect Global Leadership Team, leading key initiatives and supporting growth drivers through proactive risk mitigation and opportunity assessment.
Mr. Garrett brings to ApiJect more than a decade of legal and strategic business expertise healthcare, part of his 22 years’ experience in a broad application of the law across numerous industries. Since 2012, he served at NuVasive, Inc. as Senior Vice President for Business and Quality Systems, as well as Government & Regulations Strategy (2018-2020), Vice President, Chief Risk & Compliance Officer (2017-2019), and Vice President, Associate General Counsel (2012-2017). From 2001-2010, Mr. Garrett practiced law across diverse industries including retail, manufacturing, and biological sciences/healthcare with the firms Brobeck Phleger & Harrison LLP, (Associate, 2001-2003), Pillsbury Winthrop Shaw Pittman LLP, (Senior Associate, 2003-2008), and DLA Piper LLP, (Of Counsel, 2008–2010).
Head of Intellectual Property
Magdalena Fincham, ApiJect Head of Intellectual Property (external), has almost 25 years’ experience in Intellectual Property, both as an attorney and as a business stakeholder. She is co-founder of, and a partner in, RowanTree Law Group, a streamlined law practice focused on Intellectual Property including patent, trademark and copyright procurement, management and monetization, and due diligence services.
Previously Ms. Fincham was a Partner at Fincham Downs, LLC, a boutique intellectual property law firm. Before that she served as Director of Intellectual Property Commercialization and then as Vice President, Intellectual Property at Walker Digital, an innovation laboratory that developed, protected and commercialized its wide range of Intellectual Property assets, the best-known of which is priceline.com. Ms. Fincham’s roles at Walker including spinning off businesses, partnering with key industry stakeholders and Licensing.Learn More
Acting Head of Manufacturing
Philip Leslie has more than 30 years’ pharmaceutical manufacturing experience in Australia, New Zealand and the UK, chiefly with GlaxoSmithKline, and also with MSD and Eli Lilly. At GSK Australia, he ran the BFS production facility with a multi-disciplinary team of nearly 200 skilled people. He then led a team that designed, built and commissioned the world’s first commercially available BFS vaccine filling facility.
Also at GSK, Mr. Leslie helped oversee construction of a state-of-the-art solid dose facility that introduced one of the first electronic batch record systems with material and equipment tracking, and aided in the global rollout of an ERP system.
Mr. Leslie co-created the Pharmaceutical Innovation Centre with Monash University, supported by the Victorian Government in Australia, which inducted him into its Manufacturing Hall of Fame in 2017 in recognition of his “outstanding contribution to manufacturing excellence in Victoria.”Learn More
VP, Business Development
Ray Sell’s 25 years in the contract pharmaceuticals industry covers a wide range of customer interfacing roles. He has held key positions in leading business development efforts in sterile manufacturing, prescription softgel development and commercial manufacture, commercial and clinical packaging as well as printed components. These appointments have given Mr. Sell the opportunity to gain valuable experience throughout all facets of the pharmaceutical product lifecycle.
During his tenure at Catalent Pharma Solutions, he won three-time President’s Club recognition for being the Top Global Performer in three different business functions. He also held a leadership role as the Director, Business Development at Bellwyck Pharma Services from 2015 to 2020, and multiple Account Director and Account Manager positions at Cardinal Health PTS and PCI Printed Components. Most recently prior to joining ApiJect, Mr. Sell was Director, Business Development, CDMO North America for PCI Pharma Services.
VP, Technical Operations
Kendall Foster brings over 15 years of Vaccines and Biologics experience to his leadership post at ApiJect. He was previously the Principal Advisor at Kymanox from 2019 to 2020, providing expertise and consulting to a variety of pharma companies.
From 2016 to 2019 he held a series of increasingly responsible posts at Stellergenes Greer, a global allergy immunotheraphy company. He ended his stint at that company as VP of Technical Operations Americas, responsible for operations across three manufacturing sites. From 2007 to 2014, Mr. Foster served at Novartis Vaccines as part of the Influenza Franchise and Operations group. He supported the product development and licensure of a number of vaccines including Flucelvax, Celtura, and Fluad.
Mr. Foster also has spent his professional career across four continents, with a significant amount of time outside of the U.S., including Germany, Switzerland, South Korea, and Argentina.Learn More
Nick Robinson brings extensive executive leadership experience to his leadership role at ApiJect. His focus has been large-scale, highly sophisticated direct marketing for global financial, insurance and consumer lenders, among others, plus related specialized manufacturing, with a track record of leading innovation and profitable growth for mid-market companies, implementing business transformation and restructuring strategies, while managing risk, improving productivity and containing costs.
Mr. Robinson spent 20 years at North American Communications, Inc., one of America’s largest vertical integrated direct mail manufacturers, first as CFO, then as CEO for 16 years, annually producing over a billion pieces of mail a year for clients of this multinational manufacturing services provider. Prior to that, he served as Senior Vice President of North American Communications, Inc. before becoming President and CEO of Directcom, Inc., a database marketing and modeling agency. Earlier, he held senior management positions at data-driven marketing agencies and consulting firms, including DirectCom and Accenture.Learn More
Principal BFS Engineer
Jeff Price has 28 years of pharmaceutical experience specializing in all aspects of Blow-Fill-Seal sterile aseptic liquid filling technology. He has seven years of experience at VP level of Operations Management and Engineering Development of a privately-owned sterile inhalation generic drug manufacturing facility using Blow-Fill-Seal technology. He also authored and presented several papers on aseptic design (referenced in the 2004 FDA Aseptic Guidelines), as well as Heat Transfer analysis of the BFS process (product temperature profile during filling process) for heat sensitive products. Mr. Price has been awarded 11 patents for innovations related to BFS processes.
Mr. Price’s pharma experience includes serving as Principal Engineer at Icon Engineering, Inc.,; serving as Vice President, Operations & Engineering, Nephron Pharmaceuticals Corp., responsible for overall plant operations including BFS design, development, installation, startup, and manufacturing; and serving as Director of Engineering & Business Development for Vital Pharma, Inc.Learn More